FY2025 EPS Estimates for AC Immune Cut by HC Wainwright

Key Points

• HC Wainwright has lowered its FY2025 earnings per share (EPS) estimate for AC Immune to ($0.87), down from a previous estimate of ($0.85), while maintaining a "Buy" rating and a target price of $12.00.
• The company reported a quarterly loss of ($0.25) EPS, which missed analysts' expectations of ($0.20) EPS, reflecting challenges in revenue generation.
• AC Immune's stock has performed moderately, trading at $2.13 with a market cap of $213.87 million, amidst increased institutional investment in the company.

AC Immune (NASDAQ:ACIU - Free Report) - Analysts at HC Wainwright decreased their FY2025 earnings per share estimates for AC Immune in a report issued on Wednesday, August 6th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.87) per share for the year, down from their previous forecast of ($0.85). HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for AC Immune's current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for AC Immune's FY2026 earnings at ($0.80) EPS.

Separately, Wall Street Zen upgraded shares of AC Immune from a "hold" rating to a "buy" rating in a research report on Tuesday, May 13th.

AC Immune Stock Up 2.9%

NASDAQ ACIU traded up $0.06 during trading hours on Friday, hitting $2.14. The company's stock had a trading volume of 97,918 shares, compared to its average volume of 163,494. AC Immune has a twelve month low of $1.43 and a twelve month high of $3.98. The firm has a market capitalization of $214.88 million, a P/E ratio of -3.69 and a beta of 1.65. The stock has a fifty day moving average of $2.07 and a 200 day moving average of $2.06.

AC Immune (NASDAQ:ACIU - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.05). The business had revenue of $1.65 million for the quarter, compared to analyst estimates of $1.98 million. AC Immune had a negative return on equity of 49.35% and a negative net margin of 174.94%.

Hedge Funds Weigh In On AC Immune

Institutional investors have recently modified their holdings of the stock. Northern Trust Corp bought a new position in AC Immune during the 4th quarter worth approximately $1,088,000. Squarepoint Ops LLC acquired a new stake in AC Immune in the fourth quarter worth $118,000. Renaissance Technologies LLC boosted its position in shares of AC Immune by 14.6% during the fourth quarter. Renaissance Technologies LLC now owns 740,198 shares of the company's stock worth $1,999,000 after purchasing an additional 94,191 shares in the last quarter. Cantor Fitzgerald L. P. bought a new position in shares of AC Immune during the fourth quarter worth $68,000. Finally, Dimensional Fund Advisors LP grew its holdings in shares of AC Immune by 130.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 131,410 shares of the company's stock valued at $355,000 after buying an additional 74,358 shares during the period. 51.36% of the stock is currently owned by institutional investors and hedge funds.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.